The Safety and Effectiveness of Fozivudine Tidoxil in HIV-1 Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To identify doses of fozivudine tidoxil that are well tolerated and produce measurable
antiviral activity.
To identify the adverse event profile that defines the maximum tolerated dose. To
characterize the single- and multiple-dose pharmacokinetics of fozivudine and its
metabolites.
To correlate the adverse event profile and antiviral activity of fozivudine with
pharmacokinetic parameters.